Extracellular enveloped vaccinia virus escapes neutralization
- PMID: 8610439
- DOI: 10.1006/viro.1996.0142
Extracellular enveloped vaccinia virus escapes neutralization
Abstract
The vaccinia virus forms two morphologically distinct infectious virus particles: intracellular mature virus (IMV) and extracellular enveloped virus (EEV). The envelope of EEV is a Golgi-derived membrane (wrapping membrane). A mutant (vRB10) lacks the ability to form the EEV. In medium containing a neutralizing antibody (2D5mAb), the vRB10 mutant was diluted out from infected cells, whereas the IHD-J strain of vaccinia virus replicated well. The result indicated that the 2D5mAb specifically neutralized the IMV. The 2D5-resistant EEV appeared at 6-7 hr postinfection, and over 65% of infectious virus in the culture fluid was EEV at 48 hr after infection. The EEV was resistant not only to the 2D5mAb but also against several neutralizing antibodies, including polyclonal antivaccinia serum reactive with proteins of the wrapping membrane. Freeze-thawing and other procedures that may damage the wrapping membrane converted the EEV to a form susceptible to the antibodies. Since specific infectivity was not affected by the damage or by exposure to antibody against the wrapping membrane proteins, the wrapping membrane did not directly participate in penetration. The infection process of vaccinia virus was analyzed by comparison of responses to acid treatment between normal IMV and trypsin-treated IMV. Proteolytically activated IMV infected rapidly responding to acid. The protected form virus, which was noninfectious under usual conditions, was proteolytically activated on cell membrane then responded to the acid. Proteolysis activated the virus, and an acidic condition accelerated fusion between the activated IMV and plasma membrane. The virus in the EEV wrapping membrane was the activated form that has the capacity to fuse with the cell membrane. However, the infection of intact EEV was more sensitive against lysosomotropic agents (NH4Cl, neutral red) than that of the trypsin-activated IMV. Resistance to the 2D5mAb, sensitivity to lysosomotropic agents, and acceleration of infection by acid suggested that the intact EEV penetrated by virus-endosome membrane fusion. The combined effect of the presence of wrapping membrane and the process of internalization via an endocytic mechanism rendered EEV resistant to neutralizing antibodies.
Similar articles
-
Vaccinia virus gene A36R encodes a M(r) 43-50 K protein on the surface of extracellular enveloped virus.Virology. 1994 Oct;204(1):376-90. doi: 10.1006/viro.1994.1542. Virology. 1994. PMID: 8091668
-
Neutralizing and protective antibodies directed against vaccinia virus envelope antigens.Virology. 1999 Feb 1;254(1):71-80. doi: 10.1006/viro.1998.9516. Virology. 1999. PMID: 9927575
-
The vaccinia virus 42-kDa envelope protein is required for the envelopment and egress of extracellular virus and for virus virulence.Virology. 1993 Jun;194(2):627-37. doi: 10.1006/viro.1993.1302. Virology. 1993. PMID: 8503178
-
Studying the binding and entry of the intracellular and extracellular enveloped forms of vaccinia virus.Methods Mol Biol. 2004;269:187-204. doi: 10.1385/1-59259-789-0:187. Methods Mol Biol. 2004. PMID: 15114017 Review.
-
Extracellular enveloped vaccinia virus. Entry, egress, and evasion.Adv Exp Med Biol. 1998;440:395-414. Adv Exp Med Biol. 1998. PMID: 9782308 Review.
Cited by
-
Differences and similarities in viral life cycle progression and host cell physiology after infection of human dendritic cells with modified vaccinia virus Ankara and vaccinia virus.J Virol. 2006 Sep;80(17):8469-81. doi: 10.1128/JVI.02749-05. J Virol. 2006. PMID: 16912297 Free PMC article.
-
Resistance of a vaccinia virus A34R deletion mutant to spontaneous rupture of the outer membrane of progeny virions on the surface of infected cells.Virology. 2007 Sep 30;366(2):424-32. doi: 10.1016/j.virol.2007.05.015. Epub 2007 Jun 5. Virology. 2007. PMID: 17553539 Free PMC article.
-
First-in-man study of western reserve strain oncolytic vaccinia virus: safety, systemic spread, and antitumor activity.Mol Ther. 2015 Jan;23(1):202-14. doi: 10.1038/mt.2014.194. Epub 2014 Oct 8. Mol Ther. 2015. PMID: 25292189 Free PMC article. Clinical Trial.
-
Cloak and Dagger: Alternative Immune Evasion and Modulation Strategies of Poxviruses.Viruses. 2015 Aug 21;7(8):4800-25. doi: 10.3390/v7082844. Viruses. 2015. PMID: 26308043 Free PMC article. Review.
-
Concurrent expression of HP-NAP enhances antitumor efficacy of oncolytic vaccinia virus but not for Semliki Forest virus.Mol Ther Oncolytics. 2021 May 5;21:356-366. doi: 10.1016/j.omto.2021.04.016. eCollection 2021 Jun 25. Mol Ther Oncolytics. 2021. PMID: 34141872 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources